|
Gunawardena, K; Murray, D K; Meikle, A W (2000) Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. Prostate 44:287-95
|
|
Bansal, A; Murray, D K; Wu, J T et al. (2000) Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins. J Clin Endocrinol Metab 85:1272-6
|
|
Meikle, A W; Bansal, A; Murray, D K et al. (1999) Heritability of the symptoms of benign prostatic hyperplasia and the roles of age and zonal prostate volumes in twins. Urology 53:701-6
|
|
Meikle, A W; Swope, R E; Yin, D Y et al. (1999) Transforming growth factor beta-1 and beta-2 and type II receptor functional regulation of ALVA-101 human prostate cancer cells. Metabolism 48:1075-81
|
|
Wilson, D E; Meikle, A W; Boike, S C et al. (1998) Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men. J Clin Pharmacol 38:54-9
|
|
Ramirez, M E; McMurry, M P; Wiebke, G A et al. (1997) Evidence for sex steroid inhibition of lipoprotein lipase in men: comparison of abdominal and femoral adipose tissue. Metabolism 46:179-85
|
|
Meikle, A W; Stephenson, R A; Lewis, C M et al. (1997) Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins. J Clin Endocrinol Metab 82:571-5
|
|
Meikle, A W; Arver, S; Dobs, A S et al. (1997) Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 49:191-6
|
|
Arver, S; Dobs, A S; Meikle, A W et al. (1997) Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 47:727-37
|
|
Meikle, A W; Arver, S; Dobs, A S et al. (1996) Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. J Clin Endocrinol Metab 81:1832-40
|
Showing the most recent 10 out of 15 publications
